Autopsy report · NCT00847496

Awbat Versus Biobrane in Partial Thickness Burns

“Company went out of business”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

The University of Texas Medical Branch, Galveston

Sponsor type

University, hospital or other

Conditions

Burns

Interventions

AWBAT; Biobrane

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
  “company withdrew interest” (64% match in meaning)
• A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis
  “Drug manufacturer ceased operations” (61% match in meaning)
• The Study for Evaluate of Satety and Dfficacy of Hemostatic Device
  “The company stopped manufacturing the product” (60% match in meaning)
• A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
  “Terminated due to strategic business decision.” (60% match in meaning)
• SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
  “Supporting company withdrew interest” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.